2025
Long term feeding tube use in head and neck cancer survivors – a secondary analysis of patient and treatment related factors
Galloway T, Pugh S, Ridge J, Nguyen-Tan P, Rosenthal D, Gillison M, Garden A, Dunlap N, Caudell J, Jones C, Bauman J, Bahig H, Shenouda G, Currey A, Koyfman S, Stokes W, Read N, Lyness J, Yom S, Le Q. Long term feeding tube use in head and neck cancer survivors – a secondary analysis of patient and treatment related factors. International Journal Of Radiation Oncology • Biology • Physics 2025 PMID: 40473230, DOI: 10.1016/j.ijrobp.2025.05.064.Peer-Reviewed Original ResearchIntensity modulated radiation therapyOropharynx cancer patientsOropharynx cancerFeeding tube useTube useAccelerated fractionationTreatment initiationPredictive factorsFeeding tubeIntensity modulated radiation therapy techniquesTreated with 3DCRTSecondary analysis of patientsT4 tumor stageAnalysis of patientsTreatment related factorsPost hoc secondary analysisTreatment completionYears of smokingSecondary analysisChemoradiation trialsConcurrent chemotherapyMedian followupConcomitant boostConformal radiationRadiation therapyProfiling DNA damage response in ATM/BRCA2 carriers to inform hereditary cancer risk.
Dedousis D, Hasan A, Patel K, Czyzewicz P, Devarajan K, Hall M, Daly M, Arora S. Profiling DNA damage response in ATM/BRCA2 carriers to inform hereditary cancer risk. Journal Of Clinical Oncology 2025, 43: 10574-10574. DOI: 10.1200/jco.2025.43.16_suppl.10574.Peer-Reviewed Original ResearchGermline pathogenic variantsCancer-free controlsPeripheral blood monocytesSignificant cut-pointsCRC casesDNA damage responseCut-pointsHereditary cancer riskBenjamini-Hochberg false discovery rate methodTwo-sided Mann-Whitney testHigh-risk familiesSporadic colorectal cancerPreliminary analysis of patientsDiagnosis of cancerAnalysis of patientsHigh-risk populationFalse discovery rate methodCancer riskHigh-risk groupNegative regulator of p53Age-matched controlsDNA repair genesDamage responseMann-Whitney testNon-carrier controlsEfficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients.
Sumrall A, Allen J, Bagley S, Brundage T, Butowski N, Clymer J, Haggiagi A, Koschmann C, Kurz S, MacDonald T, Majd N, Mueller S, Ramage S, Tarapore R, Thomas R, Umemura Y, Zaky W, Odia Y. Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients. Journal Of Clinical Oncology 2025, 43: 10017-10017. DOI: 10.1200/jco.2025.43.16_suppl.10017.Peer-Reviewed Original ResearchTreatment-related adverse eventsTime to responseProspective clinical trialPartial responseRANO criteriaArm BTumor regressionDiffuse gliomasH3 K27M-mutant diffuse midline gliomaClinical trialsH3 K27M-mutant gliomasIntegrated analysis of patientsLansky performance statusTreatment-related deathsDiffuse midline gliomaAnalysis of patientsDiffuse glioma patientsClinical trial armsInvestigator-assessedPFS ratesOS ratesRadiographic responseSpinal tumorsCSF disseminationLeptomeningeal diseaseClinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
Strober B, Bukhalo M, Armstrong A, Pariser D, Kircik L, Johnson B, Montgomery P, Dickerson T. Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes. Dermatology And Therapy 2025, 15: 1787-1796. PMID: 40349264, PMCID: PMC12126387, DOI: 10.1007/s13555-025-01441-y.Peer-Reviewed Original ResearchImprove patient outcomesPatient outcomesPrescribing behaviorStatistical analysis of concordanceTreatment-as-usual armPhysician prescribing behaviorWeek 4Clinical utilityBiologic drug classesDermal biomarker patchPhysician behaviorAnalysis of patientsManagement of patientsManagement of psoriasisUtilization findingsFisher's exact testHealthcare systemMedication changesInclusion of mindfulnessPhysiciansPsoriasis AreaPatient responseProspective studyLesional skinClinical endpointsCrosstalk Between nNOS/NO and COX-2 Enhances Interferon-Gamma-Stimulated Melanoma Progression
Patel A, Tong S, Roosan M, Syed B, Awasthi A, Silverman R, Yang S. Crosstalk Between nNOS/NO and COX-2 Enhances Interferon-Gamma-Stimulated Melanoma Progression. Cancers 2025, 17: 477. PMID: 39941844, PMCID: PMC11816268, DOI: 10.3390/cancers17030477.Peer-Reviewed Original ResearchNeuronal nitric oxide synthaseIFN-gPro-tumorigenic activityCOX-2Human melanoma xenograft mouse modelMelanoma progressionMelanoma cellsFlow cytometryInduction of neuronal nitric oxide synthaseNeuronal nitric oxide synthase blockadeIn vivo antitumor efficacyMelanoma xenograft mouse modelMelanoma tumor microenvironmentLevels of PGE<sub>2</sub>PD-L1 expressionAnticancer immune responseMelanoma tumor growth in vivoCOX-2 expression levelsAnalysis of patientsInduction of COX-2Increased intracellular NO levelsSTAT3 inhibitor NapabucasinNitric oxideInhibited COX-2 expressionXenograft mouse model
2024
TRPM8 Mutations Associated With Persistent Pain After Surgical Injury of Corneal Trigeminal Axons
Ghovanloo M, Effraim P, Tyagi S, Aldrich A, Cheng X, Yuan J, Schulman B, Jacobs D, Dib-Hajj S, Waxman S. TRPM8 Mutations Associated With Persistent Pain After Surgical Injury of Corneal Trigeminal Axons. Neurology Genetics 2024, 10: e200206. PMID: 39555137, PMCID: PMC11567650, DOI: 10.1212/nxg.0000000000200206.Peer-Reviewed Original ResearchLaser-assisted in situ keratomileusisPostoperative ocular painTrigeminal ganglion neuronsOcular painMultielectrode array recordingsPersistent painGanglion neuronsLaser-assisted in situ keratomileusis surgeryAxonal injuryRat trigeminal ganglion neuronsTransient receptor potential cation channelCorneal refractive surgeryMultielectrode arraysAnalysis of patientsPatch-clamp analysisGenomic analysis of patientsWild-typePatch-clamp resultsExposure to mentholRefractive surgeryHyperpolarizing directionNeuronal hyperexcitabilityPain-freeTrigeminal axonsWT channelsProlonged intracranial catheter dwell time exacerbates penumbral stress and worsens stroke thrombectomy outcomes
Alawieh A, Elawady S, Zohdy Y, Chalhoub R, Cunningham C, Howard B, Cawley C, Barrow D, Akbik F, Pabaney A, Tong F, Al Kasab S, Jabbour P, Goyal N, Arthur A, Siddiqui F, Yoshimura S, Park M, Brinjikji W, Matouk C, Romano D, Altschul D, Williamson R, Moss M, De Leacy R, Ezzeldin M, Kan P, Levitt M, Grandhi R, Mascitelli J, Grossberg J, Spiotta A. Prolonged intracranial catheter dwell time exacerbates penumbral stress and worsens stroke thrombectomy outcomes. Journal Of NeuroInterventional Surgery 2024, 17: e303-e312. PMID: 39542713, DOI: 10.1136/jnis-2024-022271.Peer-Reviewed Original ResearchSymptomatic intracranial hemorrhageAcute ischemic strokeModified Rankin ScaleMechanical thrombectomyRecanalization successIncreasing SICHDuration of catheter useBlood flowCatheter dwell timeNegative predictors of outcomeAnalysis of patientsMulticenter international registryPropensity scorePredictors of outcomeInternal carotid arteryCerebral artery blood flowMiddle cerebral arteryArtery blood flowIn vitro modelIntracranial hemorrhageCatheter placementCatheter useCaliber catheterProcedure timeAIS patientsEquity in Modifying Plaque of Women With Undertreated Calcified Coronary Artery Disease: Design and Rationale of EMPOWER CAD study
McEntegart M, Gonzalo N, Fendelander L, West N, Lansky A. Equity in Modifying Plaque of Women With Undertreated Calcified Coronary Artery Disease: Design and Rationale of EMPOWER CAD study. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 102289. PMID: 39649816, PMCID: PMC11624350, DOI: 10.1016/j.jscai.2024.102289.Peer-Reviewed Original ResearchCoronary artery diseaseCalcified coronary artery diseasePercutaneous coronary interventionTarget lesion failureCoronary intravascular lithotripsyArtery diseaseFemale patientsIntravascular lithotripsySubcohort analysis of patientsPrevalence of coronary artery calcificationEnd pointsOptical coherence tomography imagesComposite of cardiac deathClinical events committeeSafety end pointAnalysis of patientsIndependent core laboratoryIncreased risk of mortalityIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionTarget lesion revascularizationCoronary artery calcificationEffectiveness end pointCAD studiesCardiology clinical trials12430 Urine Steroid Profiling In Patients With Unilateral And Bilateral Mild Autonomous Cortisol Secretion
Salama B, Saini J, Fell V, Atkinson E, Achenbach S. 12430 Urine Steroid Profiling In Patients With Unilateral And Bilateral Mild Autonomous Cortisol Secretion. Journal Of The Endocrine Society 2024, 8: bvae163.317. PMCID: PMC11454782, DOI: 10.1210/jendso/bvae163.317.Peer-Reviewed Original ResearchMild autonomous cortisol secretionAutonomous cortisol secretionMacronodular adrenal hyperplasiaUrine steroid profileAdrenal hyperplasiaTumor bulkDehydroepiandrosterone sulfateDST cortisolBilateral macronodular adrenal hyperplasiaInterim analysis of patientsSteroid profileCortisol secretionInterim analysisSingle-center cross-sectional studyAdrenal mass sizeUrine steroid metabolomeBilateral adrenal adenomasCompared to patientsAnalysis of patientsPost-DST cortisolProfile of patientsHigh-resolution mass spectrometry assayPrevalence of comorbiditiesSteroid profile analysisPlasma steroid profilesA Survival Analysis of Patients with Radiation-Induced Cancers after Prior Radiation for Head and Neck Cancer
Laseinde E, Guan L, Hildebrand R, Meurice N, Gensheimer M, Beadle B, Holsinger F, Sunwoo J, Baik F, Sirjani D, Divi V, Kaplan M, Pinto H, Colevas A, Rahman M, Le Q. A Survival Analysis of Patients with Radiation-Induced Cancers after Prior Radiation for Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e764. DOI: 10.1016/j.ijrobp.2024.07.1678.Peer-Reviewed Original ResearchHead and neck cancerNonsurgical groupNeck cancerRadiation treatmentTreated with non-surgical therapyIRB-approved retrospective reviewSurvival rateKaplan-Meier survival curvesSurvival rate of patientsNon-surgical therapySurvival analysis of patientsLog-rank testAnalysis of patientsNon-surgical groupNon-surgical treatmentRate of patientsRadiation-induced cancerCompare survival ratesPrior RTPostoperative RTMedian followPrior radiationSquamous histologyOverall survivalMedian ageThe Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART)
Chakrani Z, Patel M, Mellgard G, McCroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao C, Ganta T, Patel V. The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). Clinical Genitourinary Cancer 2024, 22: 102227. PMID: 39437664, DOI: 10.1016/j.clgc.2024.102227.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen Receptor AntagonistsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMolecular Targeted TherapyProgression-Free SurvivalProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRetrospective StudiesSurvival RateTreatment OutcomeConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesPSA progression free survivalOverall survivalConcurrent statinSurvival outcomesStatin useSingle-institution retrospective analysis of patientsHazard ratioSingle-institution retrospective analysisCastration-resistant prostate cancerRetrospective analysis of patientsConcurrent statin useAssociation of statin useProgression free survivalReceptor-targeted therapyCox proportional hazards regression modelsOutcomes of patientsAnalysis of patientsMultivariate survival analysisProportional hazards regression modelsTumor cell viabilityMultivariate logistic regressionHazards regression modelsEstimate hazard ratiosCharacterizing Hearing Outcomes Following Treatment of Cerebellopontine Angle Meningiomas
Papazian M, Cottrell J, Pan L, Kay-Rivest E, Friedmann D, Jethanamest D, Kondziolka D, Pacione D, Sen C, Golfinos J, Roland J, McMenomey S. Characterizing Hearing Outcomes Following Treatment of Cerebellopontine Angle Meningiomas. Journal Of Neurological Surgery Part B Skull Base 2024 DOI: 10.1055/a-2399-0081.Peer-Reviewed Original ResearchInternal auditory canalCerebellopontine angle meningiomasRisk of hearing lossCerebellopontine angleStereotactic radiosurgeryHearing outcomesHearing lossSurgical patientsPredictors of hearing lossAssociated with hearing lossMultivariate Cox proportional hazards regression modelsPoor hearing outcomesSurgically treated lesionsHearing preservation ratePostoperative hearing lossPreservation of hearingTertiary care medical centerPreoperative imaging findingsCox proportional hazards regression modelsSurgically managed patientsCranial nerve VIIIAnalysis of patientsProportional hazards regression modelsHazards regression modelsParticipants Adult patientsLate recurrence of completely resected stage I to IIIA lung adenocarcinoma
Fick C, Dunne E, Toumbacaris N, Tan K, Mastrogiacomo B, Park B, Adusumilli P, Molena D, Gray K, Sihag S, Huang J, Bott M, Rocco G, Isbell J, Jones D. Late recurrence of completely resected stage I to IIIA lung adenocarcinoma. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 445-453.e3. PMID: 38950771, PMCID: PMC11682191, DOI: 10.1016/j.jtcvs.2024.06.026.Peer-Reviewed Original ResearchAggressive pathological featuresLate recurrenceLung adenocarcinomaFollow-upPathological featuresAssociated with late recurrenceElevated risk of recurrenceFactors associated with late recurrenceRetrospective analysis of patientsRecurrence of lung adenocarcinomaHistory of lung cancerStage IIIA diseaseTime of resectionRisk of recurrenceAnalysis of patientsGenomic mutationsNeoadjuvant therapyIIIA diseaseEarly recurrenceClinicopathological variablesLogistic regression modelsRetrospective analysisLung cancerRecurrencePatientsEfficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Fava M, Stahl S, Pani L, De Martin S, Cutler A, Maletic V, Gorodetzky C, Vocci F, Sapienza F, Kosten T, Kröger C, Champasa P, O'Gorman C, Guidetti C, Alimonti A, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi C, Manfredi P, Pappagallo M. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38917366, DOI: 10.4088/jcp.24m15265.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleIntent-to-treatIntent-to-treat analysisStandard antidepressantsDepressive disorderPost Hoc AnalysisBaseline Montgomery-Asberg Depression Rating ScaleInadequate response to standard antidepressantsSevere depressionPost hoc analysis of patientsDepression Rating ScaleMajor depressive disorderAnalysis of patientsAdverse eventsMontgomery-AsbergConsistent with prior studiesPlacebo-controlled trialRating ScaleEfficacy measuresPer-protocolIntent-to-treat populationTreatment adherencePhase 3 randomized controlled trialsAdjunctive treatmentMDDAssociation of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).
Goswamy R, Yildirim A, Wei M, Liu Y, Choi Y, Brown J, Nazha B, Master V, Martini D, Carthon B, Harris W, Kucuk O, Kissick H, Hartman C, McClintock G, Vo B, Jansen C, Zhuang T, Bilen M. Association of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2024, 42: e16527-e16527. DOI: 10.1200/jco.2024.42.16_suppl.e16527.Peer-Reviewed Original ResearchCD8 T cell infiltrationMetastatic renal cell carcinomaProgression-free survivalT cell infiltrationCD8 T cellsCheckpoint inhibitorsOverall survivalTyrosine kinase inhibitorsT cellsSystemic therapyTumor microenvironmentMetastatic renal cell carcinoma patientsAssociated with favorable clinical outcomesProgression-free survival outcomesRetrospective analysis of patientsCombination checkpoint inhibitorsIntratumoral T cellsProgression free survivalImproved overall survivalFavorable clinical outcomesWinship Cancer InstituteKaplan Meier analysisAnalysis of patientsRenal cell carcinomaCox proportional hazards modelsClinical Implications of Low Body Mass Index on Endovascular Lower Extremity Revascularization
Pinto Rodriguez P, Alameddine D, Huttler J, Damara F, Slade M, Cardella J, Guzman R, Chaar C. Clinical Implications of Low Body Mass Index on Endovascular Lower Extremity Revascularization. Annals Of Vascular Surgery 2024, 106: 350-359. PMID: 38810726, DOI: 10.1016/j.avsg.2024.02.031.Peer-Reviewed Original ResearchPeripheral vascular interventionsPeripheral arterial diseaseLower body mass indexUnderweight patientsLong-term outcomesBody mass indexNonobese patientsMass indexRetrospective analysis of patientsRate of thrombotic complicationsHigher 30-day mortalityRates of amputation-free survivalRate of reinterventionOutcomes of patientsPeripheral arterial disease patientsAnalysis of patientsKaplan-Meier analysisImpact of malnutritionBaseline demographic characteristicsChronic limb-threatening ischemiaEpidemic of obesityOptimization of nutritionLonger hospital lengthAdverse limb eventsAmputation-free survivalHigh-risk features associated with recurrence in stage I lung adenocarcinoma
Fick C, Dunne E, Vanstraelen S, Toumbacaris N, Tan K, Rocco G, Molena D, Huang J, Park B, Rekhtman N, Travis W, Chaft J, Bott M, Rusch V, Adusumilli P, Sihag S, Isbell J, Jones D. High-risk features associated with recurrence in stage I lung adenocarcinoma. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 436-444.e6. PMID: 38788834, PMCID: PMC11582076, DOI: 10.1016/j.jtcvs.2024.05.009.Peer-Reviewed Original ResearchCumulative incidence of recurrenceStage I lung adenocarcinomaIncidence of recurrenceClinicopathological featuresStage I LUADCumulative incidenceHighest maximum standardized uptake valueMaximum standardized uptake valueRetrospective analysis of patientsHigh risk of recurrenceHigh riskHistory of lung cancerStage I diseaseStandardized uptake valueVisceral pleural invasionHigh-risk featuresHazard of recurrenceAssociated with recurrenceFeatures associated with recurrenceRisk of recurrenceAnalysis of patientsPrognosis of patientsDay of surgeryR0 resectionSublobar resectionComparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis
Jimenez A, Gopaul M, Asbell H, Aydemir S, Basha M, Batra A, Damien C, Day G, Eka O, Eschbach K, Fatima S, Fields M, Foreman B, Gerard E, Gofton T, Haider H, Hantus S, Hocker S, Jongeling A, Aparicio M, Kandula P, Kang P, Kazazian K, Kellogg M, Kim M, Lee J, Marcuse L, McGraw C, Mohamed W, Orozco J, Pimentel C, Punia V, Ramirez A, Steriade C, Struck A, Taraschenko O, Treister A, Yoo J, Zafar S, Zhou D, Zutshi D, Gaspard N, Hirsch L, Hanin A. Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis. Epilepsia 2024, 65: e87-e96. PMID: 38625055, DOI: 10.1111/epi.17988.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeRefractory status epilepticusMacrophage inflammatory protein-1 alphaOnset refractory status epilepticusStatus epilepticusCerebrospinal fluidFIRES patientsCerebrospinal fluid interleukin-6Magnetic resonance imaging findingsComparative analysis of patientsAnalysis of patientsChemokine ligand 2Presenting symptomsFebrile infectionsClinical featuresGastrointestinal prodromeImaging findingsInflammatory biomarkersAntiseizure medicationsInterleukin-6Epilepsy syndromesInterim analysisPatientsEpilepticusFeverDominant, Lesional Post-Traumatic Temporal Lobe Epilepsy
Herlopian A. Dominant, Lesional Post-Traumatic Temporal Lobe Epilepsy. 2024, 135-160. DOI: 10.1007/978-3-031-23828-4_7.Peer-Reviewed Original ResearchTraumatic brain injuryImprove medication complianceIntracranial monitoringPatient populationExtent of cerebral injuryAnalysis of patientsNeuroimaging modalitiesPost-traumatic epilepsyMedication adherenceMedication compliancePredictors of outcomeBrain injuryStages of epileptogenesisSurgical outcomesIctal onsetResection surgerySurgical interventionTonic seizuresCerebral injuryHistopathological analysisPatientsVisual phenomenaEpilepsyOutcomesInjuryBimekizumab Efficacy Through 3 Years in Patients with Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from BE BRIGHT
Lebwohl M, Strober B, Foley P, Langley R, Tada Y, Hampton P, Davis L, Wiegratz S, Hoepken B, Lambert J, Kokolakis G. Bimekizumab Efficacy Through 3 Years in Patients with Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from BE BRIGHT. SKIN The Journal Of Cutaneous Medicine 2024, 8: s307. DOI: 10.25251/skin.8.supp.307.Peer-Reviewed Original ResearchOpen-label extensionDermatology Life Quality IndexSevere plaque psoriasisPhase 3 trialPlaque psoriasisPooled analysisDermatology Life Quality Index 0/1Discontinued treatment due to lackModerate to severe plaque psoriasisOLE weekPooled analysis of patientsTreatment-related adverse eventsPhase 3 clinical trialsEfficacy of bimekizumabPlaque psoriasis patientsTreatment due to lackAnalysis of patientsLong-term treatment efficacyProportion of patientsNext scheduled visitNon-responder imputationLoss of responseQuality of life responsesLife Quality IndexBE VIVID
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply